More than 90% of people with generalized myasthenia gravis (gMG) treated with telitacicept for about a year achieved deep reductions in symptom severity, with more than 40% showing minimal symptoms that had little to no impact on daily life. That’s according to new data from a China-based Phase…
MGFA Scientific Session
Myasthenia Gravis News is providing virtual coverage of the Myasthenia Gravis Foundation of America’s scientific session at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting taking place Sept. 29 in Orlando, Florida. Stay tuned to this page for all the latest news.
More than 90% of people with generalized myasthenia gravis (gMG) treated with telitacicept for about a year achieved deep reductions in symptom severity, with more than 40% showing minimal symptoms that had little to no impact on daily life. That’s according to new data from a China-based Phase…
A second round of Descartes-08, Cartesian Therapeutics’ experimental CAR T-cell therapy, may allow some people with generalized myasthenia gravis (gMG) to sustain clinically meaningful symptom reduction, according to data from a clinical trial. James F. Howard Jr., MD, a trial investigator and University of North Carolina School of…
Regeneron Pharmaceuticals’ investigational therapy cemdisiran significantly reduced hospitalization rates among people with generalized myasthenia gravis (gMG) in a global clinical trial. The data from the Phase 3 NIMBLE study (NCT05070858) were presented by trial investigator Ali Habib, MD, a neurologist at the University of California, Irvine, at…
A single dose of Kyverna Therapeutics’ experimental CAR T-cell therapy mivocabtagene autoleucel (miv-cel) led to reductions in symptom severity among people with difficult-to-treat generalized myasthenia gravis (gMG) that have been sustained for up to 1.5 years. Importantly, most participants reached a state where their gMG symptoms have…